BCM
Bridgeway Capital Management Portfolio holdings
AUM
$4.21B
1-Year Return
17.73%
This Quarter Return
+6.61%
1 Year Return
+17.73%
3 Year Return
+87.27%
5 Year Return
+258.36%
10 Year Return
+515.25%
AUM
$4.18B
AUM Growth
+$413M
(+11%)
Cap. Flow
+$304M
Cap. Flow
% of AUM
7.28%
Top 10 Holdings %
Top 10 Hldgs %
6.7%
Holding
1,500
New
123
Increased
567
Reduced
324
Closed
123
Top Buys
| 1 |
NVIDIA
NVDA
|
+$24.2M |
| 2 |
JPMorgan Chase
JPM
|
+$21.2M |
| 3 |
Johnson & Johnson
JNJ
|
+$15.3M |
| 4 |
Tesla
TSLA
|
+$15.2M |
| 5 |
Microsoft
MSFT
|
+$14.9M |
Top Sells
| 1 |
TA
TravelCenters of America LLC
TA
|
+$21.5M |
| 2 |
Permian Resources
PR
|
+$15.3M |
| 3 |
PBF Energy
PBF
|
+$13.5M |
| 4 |
Netflix
NFLX
|
+$12.8M |
| 5 |
Cigna
CI
|
+$12.2M |
Sector Composition
| 1 | Financials | 24.58% |
| 2 | Consumer Discretionary | 12.2% |
| 3 | Technology | 11.89% |
| 4 | Industrials | 11.88% |
| 5 | Healthcare | 9.63% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
STRR
901
Star Equity Holdings, Inc. Common Stock
STRR
$33M
| $498K | 0.01% |
22,380
| – | – |
|
|
MKFG
902
DELISTED
Markforged Holding Corporation
MKFG
| $495K | 0.01% |
40,950
+5,950
| +17% | +$72K |
|
903
4D Molecular Therapeutics
FDMT
$322M
| $495K | 0.01% |
27,400
| – | – |
|
904
First Savings Financial Group
FSFG
$190M
| $495K | 0.01% |
37,471
+806
| +2% | +$10.6K |
|
905
Caesarstone
CSTE
$50.5M
| $490K | 0.01% |
93,600
-13,500
| -13% | -$70.7K |
|
|
OPTN
906
DELISTED
OptiNose
OPTN
| $490K | 0.01% |
26,533
+3,706
| +16% | +$68.4K |
|
907
The RealReal
REAL
$1.04B
| $490K | 0.01% |
220,500
| – | – |
|
908
Graham Corp
GHM
$527M
| $489K | 0.01% |
36,795
-3,200
| -8% | -$42.5K |
|
909
ThredUp
TDUP
$1.31B
| $488K | 0.01% |
200,000
| – | – |
|
910
Gold Resource Corp
GORO
$105M
| $488K | 0.01% |
774,098
-964,950
| -55% | -$608K |
|
911
Gencor Industries
GENC
$225M
| $485K | 0.01% |
31,150
| – | – |
|
912
Zevra Therapeutics
ZVRA
$447M
| $485K | 0.01% |
95,143
| – | – |
|
913
Avita Medical
RCEL
$112M
| $485K | 0.01% |
28,518
| – | – |
|
914
Rigel Pharmaceuticals
RIGL
$667M
| $484K | 0.01% |
37,500
+11,500
| +44% | +$148K |
|
915
Kezar Life Sciences
KZR
$29.7M
| $479K | 0.01% |
+19,550
| New | +$479K |
|
916
Actinium Pharmaceuticals
ATNM
$51.8M
| $475K | 0.01% |
63,966
| – | – |
|
917
Blend Labs
BLND
$1.07B
| $474K | 0.01% |
+500,000
| New | +$474K |
|
918
LifeMD
LFMD
$279M
| $471K | 0.01% |
108,300
+15,500
| +17% | +$67.4K |
|
919
Kewaunee Scientific
KEQU
$159M
| $471K | 0.01% |
30,400
| – | – |
|
|
FLNT
920
Fluent
FLNT
$46.8M
| $467K | 0.01% |
124,302
+1,405
| +1% | +$5.28K |
|
921
Escalade
ESCA
$171M
| $466K | 0.01% |
34,908
+400
| +1% | +$5.34K |
|
922
Altimmune
ALT
$320M
| $465K | 0.01% |
+131,700
| New | +$465K |
|
923
Red Robin
RRGB
$111M
| $463K | 0.01% |
33,500
| – | – |
|
924
Cardlytics
CDLX
$50.9M
| $461K | 0.01% |
+73,000
| New | +$461K |
|
|
DBTX
925
DELISTED
Decibel Therapeutics, Inc. Common Stock
DBTX
| $459K | 0.01% |
119,100
| – | – |
|